Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc demonstrates strong potential due to the promising efficacy data from its pipeline therapies targeting various inherited retinal diseases, which has shown significant patient-reported benefits and improvements in visual acuity. The updated label from the EMA indicates a considerable increase in the incidence of clinically relevant outcomes post-treatment, highlighting the therapies' effectiveness. Additionally, the company's ongoing advancements in clinical trials, including notable gains in near vision reported by patients and favorable feedback on regulatory pathways, suggest a constructive trajectory toward market introduction and revenue generation.

Bears say

Opus Genetics Inc. reported a reduction in R&D expenses to $6.4 million for the quarter, down from $9.0 million in the same period the previous year; however, the company has faced substantial financial losses since its inception. This trend of significant losses raises concerns about the sustainability of its operations and ability to finance ongoing projects. Furthermore, increasing market competition from emerging therapies targeting inherited retinal diseases could hinder Opus's market penetration and pricing strategies, further negatively impacting its financial outlook.

Opus Genetics (IRD) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.